Johnson & Johnson Vision Care is involved in a series of patent disputes with Novartis' eye care business unit, Ciba Vision, according to various press reports, with differing results in various national courts. The current litigation opposes J&J's Acuvue Oasys silicone hydrogel lenses against Ciba Vision's Air Optix lenses for extended wear, in a complex web of claims and counter-claims. The suits filed by Novartis in the U.S. and several European countries claim that J&J's Acuvue Oasys contact lenses infringe Novartis' Nicolson patents, covering Ciba Vision's silicone hydrogel contact lens technology and used to develop its Air Optix, 02Optix and Night & Day contact lenses. Ciba Vision has obtained a U.S. District Court decision according to which the Nicolson patents are valid and enforceable and the Acuvue Oasys contact lenses infringe said patents in the U.S. The judge has invited the parties to discuss settlement before a new hearing on Oct. 20 that may lead to an injunction in the U.S. Ciba Vision also had two other wins, one in the Dutch court and another one in the French court, which resulted in the suspension of Acuvue Oasys' sales in those countries. The British court issued a first instance ruling that the Novartis patent was invalid. Appeals are being filed against the last three decisions.